Clinical Trial examines Promising New Treatment for Graves' Disease

Graves' disease is an autoimmune condition that causes hyperthyroidism, which is an overactive thyroid gland. This condition is often associated with eye signs including proptosis, edema, and diplopia, collectively termed Graves' orbitopathy. In a clinical trial, researchers evaluated the safety and effectiveness of K1-70™, a human monoclonal TSHR (Thyroid Stimulating Hormone)-specific autoantibody that blocks ligand binding and stimulation of the receptor, in treating Graves' disease.

Clinical trial

The study involved 18 patients with Graves' disease who were stable on antithyroid drug medication. They received a single intramuscular (IM) or intravenous (IV) dose of K1-70™ during an open-label phase I ascending dose, safety, tolerability, pharmacokinetic and pharmacodynamic study. The researchers also determined the immunogenic effects of K1-70™.

The results of the clinical trial showed that K1-70™ was well-tolerated by all subjects at all doses, and no significant immunogenic response was observed. There were no deaths or serious adverse events reported. The researchers also observed an increased systemic exposure to K1-70™ following a change to IV dosing, indicating that this was the correct dosage route.

Expected pharmacodynamic effects occurred after a single IM dose of 25mg or a single IV dose of 50mg or 150mg, with fT3, fT4, and TSH levels progressing into hypothyroid ranges. Clinically significant improvements were also observed in the symptoms of both Graves' disease and Graves' orbitopathy. These included reduced tremors, improved sleep, improved mental focus, reduced toilet urgency, and reduced exophthalmos measurements and photosensitivity.

The clinical trial showed that K1-70™ was safe, well-tolerated, and produced the expected pharmacodynamic effects with no immunogenic responses. It shows considerable promise as a new drug to block the actions of thyroid stimulators on the TSHR.

Graves' disease affects about 1 in 200 people and is more common in women than men. It can cause a wide range of symptoms, including anxiety, weight loss, muscle weakness, and heat intolerance. Graves’ orbitopathy is a complication of Graves' disease and can cause eye problems such as eye pain, double vision, and bulging eyes.

Currently, the standard treatments for Graves' disease include medications that suppress the production of thyroid hormones, radioactive iodine therapy, and surgery. However, these treatments can have side effects and may not be suitable for all patients.

K1-70™ represents a new treatment option for Graves' disease that targets the underlying cause of the condition. By blocking the actions of thyroid stimulators on the TSHR, K1-70™ can help reduce the symptoms of Graves' disease and Graves' orbitopathy.

Conclusion

If you have Graves' disease and are interested in trying K1-70™, talk to your healthcare provider. They can help determine whether this treatment is appropriate for you and provide guidance on how to manage your symptoms.

The results of the clinical trial provide evidence that K1-70™ is a safe and effective treatment option for Graves' disease. While further studies are needed to confirm its efficacy, K1-70™ shows considerable promise as a new drug for the treatment of this debilitating condition.
__________